



ASX Company Announcement

MANUFACTURING PARTNERSHIP

18 November 2013

The Board of Sun Biomedical Limited (ASX: SBN), a biotechnology business, advises that the Company has today entered into a Memorandum of Understanding (MoU) with HANGZHOU BEICHI TECH CO.LTD (Beichi) under which the parties will negotiate the terms for services relating to the commercialisation of the Company's improved Oraline[®] drug testing family.

Beichi is providing development, prototyping and testing services for new strip and housing modifications to the Company's Oraline[®] drug testing devices. In addition the parties are looking to sign a manufacturing agreement for future manufacture, once final product development and testing is complete.

It is expected that the resulting agreement between Sun and Beichi may be extended to cover future products under development.

About Sun Biomedical:

Sun Biomedical Limited is an international biotechnology company with assets in the area of occupational drug testing. The company is commercialising new improved versions of its "Oraline[®]" hand held multi drug test device while also looking to increase its biotechnology investments.

About Beichi:

Beichi Tech. (Hangzhou) Co., Ltd. is one of the leading manufacturers of medical diagnostic tests and reagents, located in Zhejiang Province, China. Beichi (www.beichitech.com) manufactures high quality OEM products including fertility, drugs of abuse and infectious disease series test kits as well as Antigens, Antibodies such as HCG antibodies, and drugs of abuse antigens and antibodies to the worldwide market.

For more information about Sun Biomedical visit its corporate website at www.sunbiomed.com.au

Howard Digby
Executive Chairman
+61434987750